Vertex Pharmaceuticals
$504.73Change from previous close: −0.40%Absolute change: −$2.01
At a glance
- Revenue growth
- +8.90%
- 2025 vs 2024
- Net margin
- 32.9%
- 2024: -4.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,125 | 1,428 | 498 | 1,241 | 1,073 | 819 | 585 | 1,370 | -3,754 | 1,307 | 235 | 1,268 |
| Depreciation and amortization | 56.5 | 55.9 | 24.5 | 54.0 | 51.7 | 48.4 | 21.3 | 53.2 | 54.0 | 53.5 | 47.2 | 42.1 |
| Capital expenditure | -112 | -133 | -149 | -102 | -146 | -40.7 | -92.6 | -67.7 | -69.0 | -68.4 | -58.1 | -40.6 |
| Investing cash flow | -45.8 | -432 | -288 | -117 | -485 | -55.8 | -822 | -348 | -464 | -2,136 | -887 | -118 |
| Financing cash flow | -427 | -539 | -77.2 | -1,155 | -349 | -680 | -391 | -388 | -359 | -358 | -120 | -165 |
| Share repurchases | -474 | -565 | -131 | -1,162 | -398 | -697 | -425 | -391 | -401 | -365 | -153 | -170 |
| Debt repaid | — | — | -1.4 | -1.4 | -1.3 | -1.3 | -1.3 | -5.4 | -13.7 | -13.2 | -12.0 | -11.3 |
| Effect of exchange rates | -3.7 | -40.3 | 7.3 | -4.1 | 57.2 | 30.5 | -47.3 | 22.8 | -2.5 | -15.6 | 27.4 | -22.5 |
| Net change in cash | 649 | 417 | 140 | -34.2 | 297 | 113 | -676 | 657 | -4,578 | -1,203 | -744 | 963 |
| Free cash flow | 1,013 | 1,295 | 349 | 1,140 | 927 | 778 | 492 | 1,302 | -3,823 | 1,238 | 177 | 1,228 |
| Levered free cash flow | 757 | 1,012 | -156 | 1,019 | 912 | 802 | 185 | 1,094 | 630 | 891 | 448 | 924 |